Analyst firm TD Cowen issued buy ratings for Molecular Partners, a company based in Switzerland.
2 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firm TD Cowen issued buy ratings for Molecular Partners, a company based in Switzerland.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Molecular Partners
biopharmaceutical company based in Zürich, Switzerland
Nothing else this week.
-
Switzerland
country in Central Europe
Related events
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- Jefferies Financial Group boosted its price target and gave a buy rating, while TD Cowen started coverage and issued a buy rating for Voyager Technologies, Inc.
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.